Polo box PLK Inhibitors Target Tumors Resistant to ATP Competitive Compounds

Polo box PLK Inhibitors Target Tumors Resistant to ATP Competitive Compounds

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA213711-01A1
Agency Tracking Number: R41CA213711
Amount: $224,933.00
Phase: Phase I
Program: STTR
Awards Year: 2017
Solicitation Year: 2016
Solicitation Topic Code: NCI
Solicitation Number: PA16-303
Small Business Information
166 CABIN DR, Irmo, SC, 29063-7756
DUNS: 079204540
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 CAMPBELL MCINNES
 (803) 576-5684
 mcinnes@cop.sc.edu
Business Contact
 CAMPBELL MCINNES
Phone: (803) 338-6340
Email: mcinnes@ppipharma.com
Research Institution
 UNIVERSITY OF SOUTH CAROLINA
 MCKISSICK - 1500 PENDLETON STREET
COLUMBIA, SC, 29208-0001
 Nonprofit college or university
Abstract
Polo like kinase PLK is a central player in regulating entry into and progression through mitosis Many studies have validated PLK as an anti tumor drug target and its inhibition is potently anti proliferative to cancer cells However recent data suggests that there are two major disadvantages of the conventional approach to blocking the kinase activity of PLK First both general kinome and PLK family specificity is an issue with ATP competitive compounds as they commonly inhibit all paralogs in the Polo kinase family including PLK a known tumor suppressor Second a recent study indicates that a single point mutant in the active site of PLK Cys Val results in complete resistance to structurally distinct ATP competitive inhibitors currently in clinical trials suggesting that the emergence of resistance in the clinic against these agents is a near certainty Therefore a strategy different from targeting the catalytic domains is urgently needed PPI Pharmaceuticals will develop PLK selective non ATP competitive inhibitors as effective anti tumor therapeutics that retain activity against active site mutants resistant to conventional kinase inhibitors Such compounds will have significant potential for development as anti tumor agents with decreased likelihood of tumor resistance and off target effects PPI Pharmaceuticals will develop PLK selective non ATP competitive inhibitors as effective anti tumor therapeutics through the use of the REPLACE strategy These compounds will retain activity against active site mutants resistant to conventional kinase inhibitors Such compounds will have significant potential for development as anti tumor agents with decreased likelihood of tumor resistance and off target effects

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government